论文部分内容阅读
目的:探讨缬沙坦在维持性血液透析尿毒症患者治疗中对患者微炎症状态的影响。方法:70例行维持性血液透析的尿毒症患者随机分为两组各35例,缬沙坦组患者在透析同时口服缬沙坦治疗,对照组患者仅行透析治疗。治疗前,治疗后8周、16周时抽取两组患者静脉血检查C反应蛋白(CRP)、白细胞介素-6(IL-6)等指标水平,并作对比。结果:治疗前,两组血清CRP、IL-6水平差异无统计学意义(P>0.05)。治疗后8周、16周,缬沙坦组CRP、IL-6水平均明显下降(P<0.05),且16周时更低于8周(P<0.05);对照组三个时段CRP、IL-6水平比较,差异无统计学意义(P>0.05)。缬沙坦组治疗后8周、16周CRP、IL-6水平明显低于对照组(P<0.05)。结论:尿毒症患者透析同时辅以缬沙坦治疗,对于进一步改善微炎症状态具有积极的作用。
Objective: To investigate the effect of valsartan on microinflammatory state in maintenance hemodialysis patients. Methods: Totally 70 uremic patients undergoing maintenance hemodialysis were randomly divided into two groups of 35 patients. Patients in the valsartan group were treated with valsartan while dialysis and those in the control group were treated with dialysis only. Before treatment, 8 weeks and 16 weeks after treatment, venous blood samples of both groups were collected for C-reactive protein (CRP), interleukin-6 (IL-6) and other indicators, and compared. Results: Before treatment, there was no significant difference in CRP and IL-6 levels between the two groups (P> 0.05). The levels of CRP and IL-6 in valsartan group were significantly decreased at 8 and 16 weeks after treatment (P <0.05), and were lower than those at 8 weeks and 16 weeks (P <0.05) -6 levels, the difference was not statistically significant (P> 0.05). Valsartan group 8 weeks after treatment, 16 weeks CRP, IL-6 levels were significantly lower than the control group (P <0.05). Conclusion: Dialysis patients with uremia supplemented with valsartan treatment, to further improve the status of micro-inflammatory has a positive effect.